In addition, in a murine model of breast cancer, the production of IL-6 from adipocytes and tumor-infiltrating myeloid cells, such as macrophages, has been demonstrated to contribute, at least partly, to refractoriness to anti-VEGF treatment. This evidence concerns the gene IL6 and neoplasm.